𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Presensitization of human cells with extrinsic signals to induced chemical carcinogenesis

✍ Scribed by G. E. Milo; J. A. Dipaolo


Publisher
John Wiley and Sons
Year
1980
Tongue
French
Weight
741 KB
Volume
26
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Foreskin‐derived low‐passage human cell populations were reproducibly transformed with chemical carcinogens when the cells were blocked in G^1^, released from the block, and treated with either the carcinogen N‐methyl‐N‐nitro‐N‐nitrosoguanidine (MNNG) or with Aflatoxin BI in the S period of the cell cycle. Arginine‐and glutamine‐deficient medium was required to effectively block the cells in the G~1~ period. Estradiol, insulin, anthralin or phorbol myristate acetate sensitized the cell population to carcinogen treatment when added 10 h before the carcinogen in early S period. Presensitized cells kept blocked in G~1~ period for 48 h or longer, released and treated in S period with MNNG or Aflatoxin BI were not transformed; nor did transformation occur in presensitized cell populations treated in G~2~ (4.5 h), M (1.5 h) or G~1~ (8.2 h). Cells derived from carcinogen‐treated presensitized cells grew as colonies in soft agar at 16‐20 PDL. When cells derived from colonies isolated from the soft agar were injected subcutaneously into nude mice, tumors developed.


📜 SIMILAR VOLUMES


Characterization of human cells persiste
✍ Jui-Lien H. Li; Thomas Albrecht 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 French ⚖ 873 KB

## Abstract A non‐productive, persistent human cytomegalovirus (CMV) infection was developed in human embryo lung (LU) cells by initially using supraoptimal temperatures to restrict the replication of a recent CMV isolate (76‐24). Although CMV replication was observed in some cells within a few wee

Modulation of induced resistance to adri
✍ Brenda J. Foster; Karen R. Grotzinger; Wilma M. McKoy; Lawrence V. Rubinstein; T 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 602 KB

The clinical utility of adriamycin in the treatment of patients with metastatic breast cancer is often-limited by the development of drug resistance. It has been recognized that in addition to the development of primary resistance against adriamycin, malignant cells can simultaneously develop cross-